BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) posted its earnings results on Tuesday. The company reported ($705.20) EPS for the quarter, FiscalAI reports.

BridgeBio Oncology Therapeutics Price Performance

BBOT stock traded down $0.08 during mid-day trading on Tuesday, hitting $9.20. 202,029 shares of the stock were exchanged, compared to its average volume of 362,265. The business has a fifty day moving average price of $8.20 and a 200 day moving average price of $9.13. BridgeBio Oncology Therapeutics has a 12 month low of $7.00 and a 12 month high of $14.87. The stock has a market capitalization of $737.01 million, a price-to-earnings ratio of -4.49 and a beta of 0.35.

Analyst Upgrades and Downgrades

BBOT has been the subject of a number of research analyst reports. Oppenheimer started coverage on BridgeBio Oncology Therapeutics in a research report on Monday, June 22nd. They set an “outperform” rating and a $22.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $23.00 target price for the company. Finally, Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $24.80.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several institutional investors have recently modified their holdings of BBOT. Granahan Investment Management LLC bought a new stake in BridgeBio Oncology Therapeutics in the 1st quarter worth approximately $2,068,000. Catalio Capital Management LP bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $5,142,000. Armistice Capital LLC raised its stake in shares of BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after acquiring an additional 588,000 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $1,185,000. Finally, Paradigm Biocapital Advisors LP lifted its holdings in shares of BridgeBio Oncology Therapeutics by 21.2% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after acquiring an additional 395,608 shares during the last quarter. 54.89% of the stock is currently owned by institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.